Regenerative Medicine News
-
Showcase
ALung Announces Commercial Development of its Breakthrough Next Generation Artificial Lung
PITTSBURGH–(BUSINESS WIRE)– April 4, 2020 – ALung Technologies, Inc., the leading provider of low-flow extracorporeal carbon dioxide removal (ECCO2R) technologies for treating patients with acute respiratory failure, announced the recent initiation of commercial development of its next generation artificial lung, which expands the Company’s focus on highly efficient gas ...
-
CD Formulation Unveils Hydrogel Microneedle Patch Technology to Increase Drug Loading Capacity
CD Formulation, a leading pharmaceutical contract service company, has recently unveiled groundbreaking hydrogel microneedle patch technology aiming at increase the drug loading capacity and enhance drug delivery efficiency. The new technology represents a significant advancement in the field of transdermal drug delivery. The hydrogel microneedle patch consists of a patch with tiny microneedles ...
-
Biotech Stock News Bite - Longeveron Inc. (NASDAQ: LGVN) Stock Soars on Clinical Pipeline and 2024 Key Priorities and Goals
Investorideas.com (www.investorideas.com) Biotech Stock News Bites - Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing regenerative medicines is one of NASDAQ's top gainers today and the stock is trending on Yahoo Finance, currently trading at $3.8955, up $1.6955 or 77.0682%. The stock had a morning high of $5.47 on volume of over 36 Million/. The Company's CEO, ...
-
CD Formulation Introduces Microneedle Patch Innovations for Enhanced Drug Delivery Efficiency
CD Formulation, a leading innovator in drug delivery technologies, has recently introduced a series of groundbreaking microneedle patch innovations that promise to revolutionize the way drugs are administered. Microneedle patches are a novel drug delivery system that utilizes tiny needles to painlessly penetrate the skin's outer layer and deliver medication directly into the bloodstream. This ...
-
Alfa Chemistry Recently Launched a Sub-website for Functional Polymers
The US-based chemical supplier Alfa Chemistry announced the launch of a new sub-website for the supply of functional polymers, including Adsorptive Polymers, Biomedical Polymers, Electrofunctional Polymers, Functional PEGs, Photoactive Polymers, Silicone Polymers and more. With unstopping efforts, the company continues to offer chemicals for specialized applications, such as catalysts, fatty ...
-
Microneedle Market Projected to Reach $1.3 Billion by 2028, Reveals Latest BCC Research Study
Boston: Microneedle technology, driven by high demand in dermatologic procedures and its versatile applications in drug delivery, vaccine administration, and disease diagnostics, faces challenges in its complex manufacturing process. Ongoing research and numerous products in development make this market dynamic for newcomers entering the field. “According to the latest BCC Research study, ...
By BCC Research
-
Alfa Chemistry Shines as a Premier Recombinant Human Collagen Product Supplier
In the field of regenerative medicine and tissue engineering, the demand for collagen-based biomaterials is rapidly increasing. Collagen, the most abundant protein in the human body, plays a crucial role in maintaining the structure and function of various tissues. Recognizing the growing need for high-quality collagen products, Alfa Chemistry has emerged as a reliable supplier of recombinant ...
-
Matexcel Provides Expansive Array of Bio-ink Products for Different Applications
Matexcel, a leading innovator in advanced materials and bioengineering, today announced its diverse portfolio of bio-ink products, empowering researchers across various fields to unlock the potential of 3D bioprinting. This comprehensive range, featuring tailored bio-inks for specific applications, paves the way for revolutionary advancements in regenerative medicine, drug discovery, and beyond. ...
By Matexcel
-
CD Genomics Unveils Cutting-Edge 5mC/5hmC Sequencing Service to Drive Epigenomics Research Forward
CD Genomics, a prominent leader in the next generation sequencing arena, proudly announce the launch of a groundbreaking 5mC/5hmC sequencing service. This innovative service is poised to empower researchers by providing a deeper insight into epigenetic variations, unlocking the mysteries of epigenetics, and catalyzing pivotal advancements in the realm of life science research and precision ...
By CD Genomics
-
ATMP Sterility Testing
Stem cell therapy is a groundbreaking field in the pharmaceutical industry, offering powerful tools for treating severe diseases such as cancer. The genetic manipulations involved in this process, however, necessitate stringent regulations to ensure sterility and safety. In 2017, the Food and Drug Administration (FDA) took significant steps towards regulating stem cell therapy, marking a pivotal ...
-
Maximizing Therapeutic Potential: CD Formulation's Versatile Drug Delivery Systems Advance Pharmacokinetics and Pharmacodynamics
In the ever-evolving field of pharmaceuticals, CD Formulation has emerged as a major player in developing innovative drug delivery systems aimed at enhancing the efficacy and safety of therapies. Through its expertise in various cutting-edge technologies such as microneedle and thin film technologies, transdermal patches, microencapsulation, and nanoparticle development, CD Formulation is ...
-
CELLINK Announces CELLINK Vivoink: Our First Medical-Grade Bioink
CELLINK, a global leader in bioprinting technologies, is proud to announce a pioneering innovation in the field of regenerative medicine and tissue engineering with the launch of CELLINK Vivoink, the first-ever medical-grade bioink specially designed to support researchers on their clinical translational journey. CELLINK Vivoink is optimized for superior printability, mechanical stability, and ...
By CELLINK
-
Protecting the Immunocompromised from Invasive Mold Infection Risks in Hospitals and Buildings throughout Puerto Rico
Anyone with a weakened or suppressed immune system could be at heightened risk of developing an invasive mold infection. The Centers for Disease Control and Prevention (CDC) warns that these types of infections can occur days to weeks after exposure to fungi that live in the environment. The agency goes so far as to advise physicians to keep invasive mold infections in mind when treating people ...
-
CELLINK and the University of California, San Diego Partner to Open a 3D Bioprinting Centre of Excellence
CELLINK, a leading global provider of bioprinting technologies, and the University of California, San Diego (UCSD), a world-renowned research institution, are pleased to announce their partnership to establish a 3D bioprinting Centre of Excellence. This partnership aims to facilitate the utilization of advanced bioprinting technologies and promote cutting-edge research in the fields of drug ...
By CELLINK
-
Carcinotech and CELLINK Enter a Partnership to Develop and Commercialize Protocols for Cancer Models to Provide Improved Speed and Accuracy in the Drug Development Processes
Carcinotech and CELLINK are pleased to announce a collaborative partnership to develop and commercialize protocols for the biofabrication of 3D bioprinted tumor models based on cancer cell lines that improve accuracy and rapidly speed up drug development processes, driving down development costs and enabling an improved output. The protocols will be available for use on the BIO CELLX system ...
By CELLINK
-
CD Formulation Demonstrates Expertise in CAR-T and CAR-NK Cell Development for Drug Delivery Systems
CD Formulation, a reputable contract research organization (CRO) based in New York, has become a trusted partner for many pharmaceutical companies around the world seeking innovative drug formulation methods and solutions. Recently, CD Formulation further strengthened its role as a drug delivery expert by demonstrating its expertise in the development of cutting-edge CAR-T and CAR-NK cells for ...
-
Pushing the Boundaries of Drug Delivery: CD Formulation's Breakthrough Microsphere and Microneedle Technologies
As medicine continues to advance in this new era, drug delivery methods have been revolutionized to enhance patient comfort, improve treatment outcomes and ensure effective delivery of therapeutic compounds. CD Formulation, a leading pharmaceutical research and development company, has recently unveiled a series of cutting-edge technologies that will further revolutionize and redefine the realm ...
-
CD Genomics Introduces Advanced Exosomal RNA Sequencing Service for Enhanced Molecular Insights
CD Genomics, a leading provider of transcriptomics sequencing solutions, is pleased to announce the launch of its Exosomal RNA Sequencing service. This innovative service is set to provide researchers with comprehensive and accurate analysis of exosomal RNA, facilitating a deeper understanding of their functional significance in various biological processes. Exosomes, small extracellular ...
By CD Genomics
-
Editas Medicine Announces Positive Initial EDIT-301 Safety And Efficacy Data From The First Four Patients Treated In The RUBY Trial And The First Patient Treated In The EdiTHAL Trial
Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced positive initial safety and efficacy data from the first four patients with sickle cell disease (SCD) treated with EDIT-301 in the RUBY trial and from the first transfusion-dependent beta thalassemia patient treated in the EdiTHAL trial. The RUBY trial data will be presented in an oral presentation at ...
-
Bayer initiates phase III study to investigate aflibercept 8 mg in retinal vein occlusion
Global phase III QUASAR study will assess the efficacy and safety of aflibercept 8 mg in macular edema secondary to retinal vein occlusion (RVO) Study comes after positive data from the phase III PULSAR trial in neovascular (wet) age-related macular degeneration (nAMD) and phase II/III PHOTON trial in diabetic macular edema (DME) QUASAR is expected to enroll around 800 patients in 27 ...
By Bayer AG
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you